Co-Diagnostics, Inc. (CODX)
Stock Price:
$18.89 USD
-0.57 (-2.93%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
518.66M |
| Revenue (ttm) |
1.76M |
| Net Income (ttm) |
-5.89M |
| Shares Out |
27.46M |
| EPS (ttm) |
-0.32 |
| PE Ratio |
n/a |
| Forward PE |
9.74 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$18.89 |
| Previous Close |
$19.46 |
| Change ($) |
-0.57 |
| Change (%) |
-2.93% |
| Day's Open |
19.51 |
| Day's Range |
18.75 - 20.56 |
| Day's Volume |
2,801,756 |
| 52-Week Range |
0.80 - 29.72 |
More Stats
| Market Cap |
518.66M |
| Enterprise Value |
501.30M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
27.46M |
| Float |
24.28M |
| EPS (basic) |
-0.32 |
| EPS (diluted) |
-0.32 |
| FCF / Share |
-0.25 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.28M |
| Short Ratio |
0.37 |
| Short % of Float |
12.98% |
| Beta |
-1.32 |
| PE Ratio |
n/a |
| Forward PE |
9.74 |
| P/FCF Ratio |
n/a |
| PS Ratio |
294.68 |
| PB Ratio |
26.79 |
| Revenue |
1.76M |
| Operating Income |
-5.72M |
| Net Income |
-5.89M |
| Free Cash Flow |
-5.71M |
| Net Cash |
17.37M |
| Net Cash / Share |
0.63 |
| Gross Margin |
5.83% |
| Operating Margin |
-325.05% |
| Profit Margin |
-334.80% |
| FCF Margin |
-324.15% |
| ROA |
-26.88% |
| ROE |
-47.65% |
| ROIC |
-469.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$33.67*
(78.24% upside)
Low
30.0
Current: 18.89
High
36.0
Target: 33.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 0.21 | 0.04 | 0.01 | - | 0.01 |
| Revenue Growth | 438.63% | 420.9% | - | - | - |
| Gross Profit | 0.10 | 0.03 | 0.01 | - | 0.01 |
| Operating Income | -5.89 | -6.12 | -4.56 | -1.69 | -1.97 |
| Net Income | -6.20 | -6.27 | -6.96 | -1.93 | -2.04 |
| Shares Outstanding | 16.76 | 12.48 | 10.96 | 9.88 | 9.36 |
| Earnings Per Share | -0.36 | -0.50 | -0.63 | -0.20 | -0.22 |
| Operating Cash Flow | -5.53 | -4.08 | -3.21 | -1.31 | -1.53 |
| Capital Expenditures | -0.11 | -0.04 | -0.13 | -0.01 | -0.12 |
| Free Cash Flow | -5.64 | -4.12 | -3.34 | -1.32 | -1.65 |
| Cash & Equivalents | 0.89 | 0.95 | 3.53 | 1.00 | 0.03 |
| Total Debt | - | 1.91 | - | 3.39 | 1.01 |
| Net Cash / Debt | 0.89 | -0.96 | 3.53 | -2.40 | -0.98 |
| Assets | 2.22 | 1.55 | 4.66 | 1.30 | 0.37 |
| Liabilities | 0.48 | 2.61 | 0.81 | 4.29 | 1.52 |
| Book Value | 1.74 | -1.06 | 3.85 | -2.99 | -1.15 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Co-Diagnostics, Inc. |
| Country |
United States |
| Employees |
29 |
| CEO |
Dwight Howard Egan |
Stock Information
| Ticker Symbol |
CODX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: CODX |
| IPO Date |
July 12, 2017 |
Description
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.